The DOI matches its Crossref record.
Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients
Open accessAbstract
Background We investigated whether serum concentration of carboxy-terminal propeptide of procollagen type I (PIP), a marker of collagen type I synthesis, can be used to assess the ability of antihypertensive treatment to regress myocardial fibrosis in hypertensive patients. Methods and Results The study was performed in 37 patients with essential hypertension and hypertensive heart disease. After randomization, 21 patients were assigned to losartan and 16 patients to amlodipine treatment. At baseline and after 12 months, right septal endomyocardial biopsies were performed to quantify collagen volume fraction (CVF) on picrosirius red–stained sections with an automated image-analysis system. Serum PIP was measured by specific radioimmunoassay. Nineteen patients in the losartan group and 11 in the amlodipine group finished the study. Time-course changes in blood pressure during treatment were similar in the 2 groups of patients. In losartan-treated patients, CVF decreased from 5.65±2.03% to 3.96±1.46% ( P <0.01) and PIP from 127±30 to 99±26 μg/L ( P <0.01). Neither CVF or PIP changed significantly in amlodipine-treated patients. CVF was directly correlated with PIP ( r =0.44, P <0.001) in all hypertensives before and after treatment. Conclusions These findings suggest that the ability of antihypertensive treatment to regress fibrosis in hypertensives with biopsy-proven myocardial fibrosis is independent of its antihypertensive efficacy. Our data also suggest that blockade of the angiotensin II type 1 receptor is associated with inhibition of collagen type I synthesis and regression of myocardial fibrosis in hypertensives. Thus, determination of serum PIP may be useful to assess the cardioreparative properties of antihypertensive treatment in hypertensives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathological Ventricular Remodeling: Mechanisms: Part 1 of 2
Burchfield, J. S., Xie, M., & Hill, J. A. (2013) · Circulation · doi:10.1161/circulationaha.113.001878 · Cited by 766
Dweck, M. R., Boon, N. A., & Newby, D. E. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.093 · Cited by 692
“It is therefore encouraging that in patients with hypertension, ACE inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy beyond their effects on blood pressure, with favorable effects on myocardial fibrosis, diastolic function, and clinical outcomes (88,89).”
BackgroundMadrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 647
Díez, J., Querejeta, R., López, B., González, A., Larman, M., & Martínez Ubago, J. L. (2002) · Circulation · doi:10.1161/01.cir.0000017264.66561.3d · Cited by 637
Self-citationQuerejeta, R., López, B., González, A., Sánchez, E., Larman, M., Martínez Ubago, J. L., & Díez, J. (2004) · Circulation · doi:10.1161/01.cir.0000140973.60992.9a · Cited by 449
Self-citationInflammation in the genesis and perpetuation of atrial fibrillation
Engelmann, M. D. M., & Svendsen, J. H. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi350 · Cited by 416
Ahmed, S. H., Clark, L. L., Pennington, W. R., Webb, C. S., Bonnema, D. D., Leonardi, A. H., McClure, C. D., Spinale, F. G., & Zile, M. R. (2006) · Circulation · doi:10.1161/circulationaha.105.573865 · Cited by 386
Candidate‐based proteomics in the search for biomarkers of cardiovascular disease
Anderson, L. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2004.080473 · Cited by 378
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches
López, B., Ravassa, S., Moreno, M. U., José, G. S., Beaumont, J., González, A., & Díez, J. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00504-1 · Cited by 361
Fibrosis and Cardiac Arrhythmias
de Jong, S., van Veen, T. A. B., van Rijen, H. V. M., & de Bakker, J. M. T. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318207a35f · Cited by 360
Ehrlich, J. R., Hohnloser, S. H., & Nattel, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi668 · Cited by 304
Cardiac Fibrosis as a Cause of Diastolic Dysfunction
Burlew, B. S., & Weber, K. T. (2002) · Herz · doi:10.1007/s00059-002-2354-y · Cited by 257
Update on the Association of Inflammation and Atrial Fibrillation
PATEL, P., DOKAINISH, H., TSAI, P., & LAKKIS, N. (2010) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2010.01774.x · Cited by 190
Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade
Kosmala, W., Przewlocka-Kosmala, M., Szczepanik-Osadnik, H., Mysiak, A., & Marwick, T. H. (2013) · Heart · doi:10.1136/heartjnl-2012-303329 · Cited by 104
Metadata
- Authors
- López, B., Querejeta, R., Varo, N., González, A., Larman, M., Martínez Ubago, J. L., & Díez, J.
- Venue
- Circulation
- Published
- 2001-07-17
- Volume
- 104
- Issue
- 3
- Pages
- 286-291
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2134264965
- Cited by
- 251
- References
- 0
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.